Key points are not available for this paper at this time.
Ceftazidime-avibactam may be a reasonable alternative to colistin in the treatment of K. pneumoniae carbapenemase-producing CRE infections. These findings require confirmation in a randomized controlled trial.
Duin et al. (Mon,) studied this question.